BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2027-02
126 industry Phase 2/3 trial readout(s) and 3 FDA decision event(s). Active trials only; estimated dates often slip.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-02-01 (month) | PDUFA date (company-disclosed) | pending | ANAPTYSBIO, INC ANAB | PDUFA February 2027 - ANAPTYSBIO, INC | |
| 2027-02-28 | PDUFA date (company-disclosed) | pending | Apnimed, Inc. APMD | PDUFA February 28, 2027 - Apnimed, Inc. | |
| 2027-02-28 | PDUFA date (company-disclosed) | pending | PALVELLA THERAPEUTICS, INC. PVLA | PDUFA February 28, 2027 - PALVELLA THERAPEUTICS, INC. |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-02 est. | P1/P2 | Lumicell, Inc. | NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer | active not recruiting | 66 |
| 2027-02 est. | P1/P2 | AbbVie ABBV | NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Acute Myeloid Leukemia | active not recruiting | 218 |
| 2027-02 est. | P1/P2 | Prevail Therapeutics | NCT04411654 Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) | Gaucher Disease, Type 2 | active not recruiting | 7 |
| 2027-02 est. | P3 | SK Life Science, Inc. | NCT05219617 Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | Seizures; Lennox Gastaut Syndrome | recruiting | 252 |
| 2027-02 est. | P1/P2 | Day One Biopharmaceuticals, Inc. | NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Triple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Can | recruiting | 360 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2027-02 est. | P1/P2 | SparingVision | NCT05748873 Promising ROd-cone DYstrophy Gene therapY | Retinitis Pigmentosa | active not recruiting | 33 |
| 2027-02 est. | P3 | Celltrion | NCT05906992 A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | recruiting | 512 |
| 2027-02 est. | P1/P2 | Beijing Scitech-Mq Pharmaceuticals Limited | NCT06127238 Study of ST-1898 in Advanced Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | active not recruiting | 90 |
| 2027-02 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cance | recruiting | 250 |
| 2027-02 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06241846 A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer (mCRPC) | recruiting | 100 |
| 2027-02 est. | P3 | EMS | NCT06268054 Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea | Primary Dysmenorrhea | not yet recruiting | 78 |
| 2027-02 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06323213 Efficacy and Safety Study of 610 in Patients With Severe Asthma | Asthma | recruiting | 480 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Fol | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive | active not recruiting | 108 |
| 2027-02 est. | P2 | Eli Lilly and Company LLY | NCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Glioma | active not recruiting | 45 |
| 2027-02 est. | P2 | Genelux Corporation GNLX | NCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; M | recruiting | 142 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin | Hidradenitis Suppurativa; Atopic Dermatitis | recruiting | 60 |
| 2027-02 est. | P1/P2 | DualityBio Inc. | NCT06554795 First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Solid Tumor, Adult | recruiting | 360 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | Migraine | active not recruiting | 309 |
| 2027-02 est. | P2 | 60 Degrees Pharmaceuticals LLC SXTP | NCT06656351 B-FREE Chronic Babesiosis Study | Chronic Babesiosis | recruiting | 40 |
| 2027-02 est. | P3 | Eli Lilly and Company LLY | NCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Obesity; Overweight | recruiting | 125 |
| 2027-02 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06680947 A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | Asthma | active not recruiting | 225 |
| 2027-02 est. | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT06783257 Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding | Peptic Ulcer Bleeding | not yet recruiting | 150 |
| 2027-02 est. | P3 | Trust Bio-sonics, Inc. | NCT06815627 Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography | Cardiac Diseases | active not recruiting | 150 |
| 2027-02 est. | P2 | Bavarian Nordic | NCT06899802 A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine | Encephalitis | active not recruiting | 411 |
| 2027-02 est. | P3 | Eurofarma Laboratorios S.A. | NCT06905210 Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris | Acne Vulgaris; Acne Vulgaris on the Face | recruiting | 531 |
| 2027-02 est. | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT06937203 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity; Diabetes Mellitus, Type 2 | recruiting | 150 |
| 2027-02 est. | P3 | Celltrion | NCT06939595 A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | Non Squamous Non Small Cell Lung Cancer | active not recruiting | 225 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | recruiting | 180 |
| 2027-02 est. | P3 | Kodiak Sciences Inc KOD | NCT06996080 A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | Macular Edema Secondary to Inflammation | recruiting | 300 |
| 2027-02 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07060456 Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | Type 2 Diabetes | recruiting | 300 |
| 2027-02 est. | P3 | Keymed Biosciences Co.Ltd | NCT07106372 A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Atopic Dermatitis | not yet recruiting | 240 |
| 2027-02 est. | P1/P2 | AbCellera Biologics Inc. ABCL | NCT07118891 Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | Vasomotor Symptoms Associated With Menopause; Healthy Volunteers | active not recruiting | 136 |
| 2027-02 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07136142 A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | Malignant Solid Tumor | recruiting | 150 |
| 2027-02 est. | P1/P2 | GI Innovation, Inc. | NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNS | recruiting | 102 |
| 2027-02 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07173556 A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer | Advanced Breast Cancer | not yet recruiting | 96 |
| 2027-02 est. | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT07184645 A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | Atopic Dermatitis (AD) | not yet recruiting | 198 |
| 2027-02 est. | P2 | Eli Lilly and Company LLY | NCT07223840 A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse | Smoking | recruiting | 222 |
| 2027-02 est. | P2 | Suzhou HepaThera Biotech Co., Ltd. | NCT07245953 A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | active not recruiting | 60 |
| 2027-02 est. | P1/P2 | Sovargen | NCT07287202 Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalence | Focal Cortical Dysplasia; Tuberous Sclerosis Complex (TSC); Hemimegalencephaly | recruiting | 12 |
| 2027-02 est. | P2 | RDC Clinical Pty Ltd | NCT07315516 Sleep and Stress Study | Sleep Disorder (Disorder); Stress; Anxiety | recruiting | 240 |
| 2027-02 est. | P2 | Candel Therapeutics, Inc. CADL | NCT07332000 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma) | recruiting | 45 |
| 2027-02 est. | P2 | Neurocrine Biosciences NBIX | NCT07365462 Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | Tardive Dyskinesia | recruiting | 100 |
| 2027-02 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07367516 Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Esophageal Cancer | recruiting | 105 |
| 2027-02 est. | P1/P2 | Bond Biosciences | NCT07371793 A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis | Hereditary Hemochromatosis | recruiting | 34 |
| 2027-02 est. | P2 | Sanaria Inc. | NCT07385287 Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults | Malaria (Plasmodium Falciparum) | recruiting | 180 |
| 2027-02 est. | P2 | Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. | NCT07395986 A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract | Age Related Cataracts | active not recruiting | 8 |
| 2027-02 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07464587 Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | recruiting | 800 |
| 2027-02 est. | P1/P2 | RIGImmune Inc. | NCT07488897 RIG 101 Trial in Healthy Adults and Adults With Asthma | Healthy Adult Participants; Asthma Exacerbation; Safety and Efficacy | recruiting | 82 |
| 2027-02 est. | P2 | Rivus Pharmaceuticals, Inc. | NCT07491458 A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis ( | MASH - Metabolic Dysfunction-Associated Steatohepatitis | recruiting | 180 |
| 2027-02 est. | P3 | Alcon Research ALC | NCT07531043 Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | Ocular Hyperemia | recruiting | 230 |
| 2027-02 est. | P2 | Almirall, S.A. | NCT07547813 A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | recruiting | 50 |
| 2027-02 est. | P2 | TearSolutions, Inc. | NCT07568730 A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic K | Neurotrophic Keratitis | recruiting | 54 |
| 2027-02 est. | P2 | Enlivex Therapeutics Ltd. ENLV | NCT07580716 Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis | Primary Knee Osteoarthritis | recruiting | 182 |
| 2027-02 est. | P3 | TriGemX Bio, Inc. | NCT07645924 A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | Migraine | recruiting | 1800 |
| 2027-02 est. | P3 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | NCT07663903 Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment | Severe Hemophilia A | active not recruiting | 60 |
| 2027-02 est. | P2 | Clarent Biopharma, Inc. | NCT07706530 Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) | Arthritic Psoriasis | not yet recruiting | 240 |
| 2027-02 est. | P2 | Shanghai RAAS Blood Products Co., Ltd. | NCT07711158 A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency | Factor VII Deficiency | not yet recruiting | 12 |
| 2027-02 est. | P2 | Antag Therapeutics | NCT07724340 A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweigh | Adults With Overweight/Obesity and Type 2 Diabetes | active not recruiting | 150 |
| 2027-02 est. | P2 | Liquidia Technologies, Inc. LQDA | NCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks | Raynaud's Phenomenon Secondary to Systemic Sclerosis | not yet recruiting | 75 |
| 2027-02 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07767513 Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events | Lipoprotein Disorder | recruiting | 60 |
| 2027-02 est. | P2 | Bausch & Lomb Incorporated BLCO | NCT07778888 BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial | Dry Eye Disease | recruiting | 20 |
| 2027-02 est. | P3 | PT Bio Farma | NCT07854847 Study Interchangeability Hep-B Vaccine Administered at Birth Dose | Vaccination Adverse Event; Immunogenicity, Vaccine | not yet recruiting | 270 |
| 2027-02 est. | P3 | ScandiBio Therapeutics AB | NCT07889284 Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout | Gout Disease | not yet recruiting | 336 |
| 2027-02-01 est. | P2 | Novartis Pharmaceuticals NVS | NCT02934568 Ribociclib (LEE011) Rollover Study for Continued Access | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Can | active not recruiting | 22 |
| 2027-02-01 est. | P1/P2 | Amplia Therapeutics Limited | NCT05355298 ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | Pancreatic Cancer; PDAC; Pancreatic Ductal Adenocarcinoma | active not recruiting | 62 |
| 2027-02-01 est. | P1/P2 | Gracell Biotechnologies (Shanghai) Co., Ltd. | NCT06530849 A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | Refractory Systemic Lupus Erythematosus | active not recruiting | 20 |
| 2027-02-01 est. | P2 | AB Biotics, SA | NCT07193927 Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Fatty Liver Disease, Nonalcoholic; | recruiting | 60 |
| 2027-02-01 est. | P2 | Boryung Pharmaceutical Co., Ltd | NCT07373613 A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | Essential Hypertension | not yet recruiting | 330 |
| 2027-02-02 est. | P2 | Novartis Pharmaceuticals NVS | NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Melanoma | active not recruiting | 134 |
| 2027-02-02 est. | P2/P3 | Noema Pharma AG | NCT05217628 An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | Trigeminal Neuralgia | active not recruiting | 166 |
| 2027-02-02 est. | P1/P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06185764 A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | Myotonic Dystrophy Type 1 (DM1) | active not recruiting | 47 |
| 2027-02-02 est. | P2 | Cellvax Therapeutics Inc | NCT06636682 FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | Prostate Cancer (Adenocarcinoma); Prostate CA; Prostate Cancers; Prostate Cancer (Post Prostatectomy | recruiting | 100 |
| 2027-02-03 est. | P2 | InventVacc Biologicals Inc. | NCT07743008 Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine | Haemophilus Influenzae; Haemophilus Influenzae Type a | active not recruiting | 47 |
| 2027-02-04 est. | P3 | Hoffmann-La Roche | NCT04657289 A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age | Neovascular Age-related Macular Degeneration (nAMD) | active not recruiting | 451 |
| 2027-02-04 est. | P3 | Janssen Research & Development, LLC | NCT06741969 Nipocalimab in Moderate to Severe Sjogren's Disease | Sjogrens Syndrome | active not recruiting | 655 |
| 2027-02-04 est. | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07521631 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Obesity | recruiting | 372 |
| 2027-02-04 est. | P2 | Novartis Pharmaceuticals NVS | NCT07811908 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) | Uncomplicated Plasmodium Falciparum Malaria | recruiting | 120 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
| 2027-02-05 est. | P2 | Takeda TAK | NCT07244263 A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 91 |
| 2027-02-05 est. | P1/P2 | Applied Biology, Inc. | NCT07397325 Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | Chemotherapy Induced Alopecia; Chemotherapy Side Effects | recruiting | 60 |
| 2027-02-05 est. | P2 | EktaH | NCT07882654 A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS. | Obesity / Overweight; Obesity (BMI Equal to or >30) | not yet recruiting | 31 |
| 2027-02-07 est. | P1/P2 | Intra-IMMUSG Pte Ltd | NCT07547228 A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age Related Macular Degeneration | recruiting | 15 |
| 2027-02-08 est. | P2 | Abcentra | NCT06927739 Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Acute Coronary Syndromes; Coronary Arterial Disease (CAD); Inflammation; Heart Disease; Myocardial I | recruiting | 240 |
| 2027-02-09 est. | P2 | Aston Sci. Inc. | NCT05771584 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer | Gastric Cancer | active not recruiting | 24 |
| 2027-02-09 est. | P2 | Sanofi SNY | NCT07170917 Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | recruiting | 208 |
| 2027-02-09 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07175428 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Atrial Fibrillation (AF) | recruiting | 1200 |
| 2027-02-10 est. | P3 | Janssen Research & Development, LLC | NCT06260163 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | active not recruiting | 112 |
| 2027-02-10 est. | P2 | AstraZeneca AZN | NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | active not recruiting | 127 |
| 2027-02-10 est. | P2 | Shanghai Henlius Biotech | NCT06349980 A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advan | Carcinoma, Hepatocellular | recruiting | 117 |
| 2027-02-10 est. | P3 | Janssen Research & Development, LLC | NCT06807424 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthriti | Arthritis, Psoriatic | active not recruiting | 813 |
| 2027-02-10 est. | P3 | Takeda TAK | NCT06973304 A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Short Bowel Syndrome | active not recruiting | 13 |
| 2027-02-11 est. | P2 | Sanofi SNY | NCT06984627 A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | Graves' Disease | recruiting | 30 |
| 2027-02-11 est. | P2 | AstraZeneca AZN | NCT07215702 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | Sepsis; Acute Kidney Injury | recruiting | 124 |
| 2027-02-11 est. | P2 | Gan & Lee Pharmaceuticals. | NCT07387003 Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | Type 2 Diabetes (T2DM) | not yet recruiting | 345 |
| 2027-02-12 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkin Lymphoma | active not recruiting | 340 |
| 2027-02-12 est. | P3 | Ocugen OCGN | NCT06388200 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | Retinitis Pigmentosa | active not recruiting | 140 |
| 2027-02-12 est. | P1/P2 | Jecho Biopharmaceuticals Co., Ltd. | NCT07579741 A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | HIV Infections | recruiting | 30 |
| 2027-02-13 est. | P3 | Epizyme, Inc. | NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in | Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma | active not recruiting | 599 |
| 2027-02-13 est. | P3 | SK Bioscience Co., Ltd. | NCT07415252 SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | Varicella (Chickenpox) | recruiting | 780 |
| 2027-02-14 est. | P1/P2 | Evopoint Biosciences Inc. | NCT06987500 A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | Tumor, Solid | recruiting | 132 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07437547 BPC 157 for Acute Hamstring Muscle Strain Repair | Hamstring Muscle Strain; Skeletal Muscle Injury | recruiting | 120 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07437560 Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo | NonSegmental Vitiligo; Nonsegmental Vitiligo (Stable) | recruiting | 60 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07437586 Topical GHK-Cu Gel for Acute Skin Wound Healing | Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) | recruiting | 60 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07467863 Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC | Non-Small Cell Lung Cancer; Advanced/Metastatic NSCLC | recruiting | 48 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07480213 Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; SCLC, Extensive Stage | recruiting | 60 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07480928 Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease | recruiting | 42 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07481734 Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis | recruiting | 120 |
| 2027-02-14 est. | P3 | Hudson Biotech | NCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | recruiting | 2539 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07486089 Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer; Triple-Negative Breast | recruiting | 60 |
| 2027-02-14 est. | P1/P2 | Hudson Biotech | NCT07487363 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | Atherosclerotic Cardiovascular Diseases; Endothelial Dysfunction | recruiting | 80 |
| 2027-02-14 est. | P2 | Eisai Inc. | NCT07493265 A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | Narcolepsy | recruiting | 64 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07505745 MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | Prediabetes; Insulin Resistance; Overweight/Obesity | recruiting | 120 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07589530 Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors | Advanced Solid Tumors; Metastatic Solid Tumors; TROP2-Expressing Solid Tumors | recruiting | 60 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07744256 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC | recruiting | 60 |
| 2027-02-15 est. | P3 | Acerta Pharma BV | NCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Lymphoma, Mantle Cell | active not recruiting | 635 |
| 2027-02-15 est. | P3 | Albireo, an Ipsen Company | NCT05035030 Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Alagille Syndrome | active not recruiting | 62 |
| 2027-02-15 est. | P3 | ModernaTX, Inc. | NCT06592794 A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | active not recruiting | 37864 |
| 2027-02-15 est. | P3 | CanSino Biologics Inc. | NCT07017777 A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) | Pneumococcal Infections; Streptococcal Infections; Bacterial Infections | active not recruiting | 600 |
| 2027-02-15 est. | P1/P2 | Ikaria Bioscience Pty Ltd | NCT07245771 Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination | Obesity &Amp; Overweight | recruiting | 104 |
| 2027-02-16 est. | P3 | Bristol-Myers Squibb BMY | NCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cel | Carcinoma, Non-Small-Cell Lung | active not recruiting | 190 |
| 2027-02-16 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07082114 A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | recruiting | 800 |
| 2027-02-17 est. | P2 | Takeda TAK | NCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | recruiting | 268 |
| 2027-02-17 est. | P3 | Sanofi SNY | NCT07424144 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 59 |
| 2027-02-17 est. | P1/P2 | Beijing Biotech | NCT07480954 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma; Recurrent or Refr | recruiting | 36 |
| 2027-02-17 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT07486960 Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | Psoriatic Arthritis | active not recruiting | 140 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.